Skip Navigation


Journal of the National Cancer Institute Advance Access originally published online on September 9, 2008
JNCI Journal of the National Cancer Institute 2008 100(18):1276-1278; doi:10.1093/jnci/djn335
This Article
Right arrow Full Text Freely available
Right arrow FREE Full Text (PDF) Freely available
Right arrow All Versions of this Article:
100/18/1276    most recent
djn335v1
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrow Search for citing articles in:
ISI Web of Science (1)
Right arrow Request Permissions
Google Scholar
Right arrow Articles by Brower, V.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Brower, V.
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

© Oxford University Press 2008.

NEWS

Cancer Gene Therapy Steadily Advances

Vicki Brower, This is the first of a two-part series on gene therapy.

The first 150 words of the full text of this article appear below.

Since 1999, when gene therapy research was blemished with the death of Jesse Gelsinger, the first publicly identified person to die in a gene therapy trial, the field has been slowly advancing. Positive phase III trial results with a first-generation gene therapy for cancer, known as Advexin, were announced this spring along with other earlier-stage studies. Researchers in the field hope that these advances will help restore respect to a treatment modality that, alone and in combination with chemotherapy and radiation, shows promise.

Advexin targets the cancer suppressor gene p53, and although this single-gene approach is finally having success—in August, Advexin was accepted for review by the European Medicines Agency based on the phase III trial results that showed that certain patients responded well to Advexin—two decades of research has led many scientists to believe that replacing one gene may not be the best strategy for a complex, multigenic disease . . . [Full Text of this Article]

Multiple Challenges

Treating Metastases

Exploiting Viral Attraction

Retooling Immunotherapies


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?